Inhibiting histone deacetylase 1 suppresses both inflammation and bone loss in arthritis

Rheumatology (United Kingdom)

Volumn 54, Issue 9, 2015, Pages 1713-1723

  Cantley, Melissa D ^a   Fairlie, David P ^b   Bartold, P Mark ^a   Marino, Victor ^a   Gupta, Praveer K ^b   Haynes, David R ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Bone loss; Collagen antibody induced arthritis; Histone deacetylase 1; Inflammation; Osteoclasts

Indexed keywords

CHEMOKINE; COLONY STIMULATING FACTOR 1; CYTOKINE; ENTINOSTAT; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE INHIBITOR; INTERLEUKIN 1; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; NW 21; OSTEOCLAST DIFFERENTIATION FACTOR; RANTES; TRANSCRIPTION FACTOR NFAT; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTHRITIS; ARTICLE; BONE DESTRUCTION; BONE MASS; CARTILAGE DEGENERATION; CELL INFILTRATION; CELL VIABILITY; COMPUTED TOMOGRAPHY SCANNER; CONTROLLED STUDY; ENZYME INHIBITION; FEMALE; GENE EXPRESSION; IC50; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; INFLAMMATORY CELL; MICRO-COMPUTED TOMOGRAPHY; MONOCYTE; MOUSE; MULTINUCLEAR CELL; NONHUMAN; OSTEOCLAST ACTIVITY; OSTEOCLASTOGENESIS; OSTEOLYSIS; PRE-CLINICAL IMAGING DEVICE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RHEUMATOID ARTHRITIS; WEIGHT REDUCTION;

EID: 84983113549     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kev022     Document Type: Article

References (49)

1. Australian Institute of Health and Welfare. Arthritis and musculoskeletal conditions in Australia 2005: with a focus on osteoarthritis, rheumatoid arthritis and osteoporosis. Arthritis series no. 1. Cat. no. PHE67. Canberra, ACT, Australia: AIHW, 2005.
2. Fujikawa Y, Sabokbar A, Neale S, Athanasou NA. Human osteoclast formation and bone resorption by monocytes and synovial macrophages in rheumatoid arthritis. Ann Rheum Dis 1996;55:816-22.
3. Haynes DR, Crotti TN, Loric M et al. Osteoprotegerin and receptor activator of nuclear factor kappaB ligand (RANKL) regulate osteoclast formation by cells in the human rheumatoid arthritic joint. Rheumatology 2001;40: 623-30.
4. Suzuki Y, Tsutsumi Y, Nakagawa M et al. Osteoclast-like cells in an in vitro model of bone destruction by rheumatoid synovium. Rheumatology 2001;40:673-82.
5. Toritsuka Y, Nakamura N, Lee SB et al. Osteoclastogenesis in iliac bone marrow of patients with rheumatoid arthritis. J Rheumatol 1997;24:1690-6.
6. Pettit AR, Ji H, von Stechow D et al. TRANCE/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis. Am J Pathol 2001;159:1689-99.
7. Redlich K, Hayer S, Ricci R et al. Osteoclasts are essential for TNF-alpha-mediated joint destruction. J Clin Invest 2002;110:1419-27.
8. Schett G. Erosive arthritis. Arthritis Res Ther 2007;9(Suppl 1):S2.
9. De Vries F, Bracke M, Leufkens HG et al. Fracture risk with intermittent high-dose oral glucocorticoid therapy. Arthritis Rheum 2007;56:208-14.
10. Mohan N, Edwards ET, Cupps TR et al. Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum 2001;44: 2862-9.
11. Tavares R, Pope JE, Tremblay JL et al. Time to diseasemodifying antirheumatic drug treatment in rheumatoid arthritis and its predictors: a national, multicenter, retrospective cohort. J Rheumatol 2012;39:2088-97.
12. Keystone E. Recent concepts in the inhibition of radiographic progression with biologics. Curr Opin Rheumatol 2009;21:231-7.
13. Kristensen LE, Saxne T, Nilsson JA, Geborek P. Impact of concomitant DMARD therapy on adherence to treatment with etanercept and infliximab in rheumatoid arthritis. Results from a six-year observational study in southern Sweden. Arthritis Res Ther 2006;8:R174.
14. Yang XJ, Seto E. The Rpd3/Hda1 family of lysine deacetylases: from bacteria and yeast to mice and men. Nat Rev Mol Cell Biol 2008;9:206-18.
15. Slingerland M, Guchelaar HJ, Gelderblom H. Histone deacetylase inhibitors: an overview of the clinical studies in solid tumors. Anticancer Drugs 2014;25:140-9.
16. Leoni F, Fossati G, Lewis EC et al. The histone deacetylase inhibitor ITF2357 reduces production of pro-inflammatory cytokines in vitro and systemic inflammation in vivo. Mol Med 2005;11:1-15.
17. Dinarello CA, Fossati G, Mascagni P. Histone deacetylase inhibitors for treating a spectrum of diseases not related to cancer. Mol Med 2011;17:333-52.
18. Lin HS, Hu CY, Chan HY et al. Anti-rheumatic activities of histone deacetylase (HDAC) inhibitors in vivo in collageninduced arthritis in rodents. Br J Pharmacol 2007;150: 862-72.
19. Nakamura T, Kukita T, Shobuike T et al. Inhibition of histone deacetylase suppresses osteoclastogenesis and bone destruction by inducing IFN-beta production. J Immunol 2005;175:5809-16.
20. Joosten LA, Leoni F, Meghji S, Mascagni P. Inhibition of HDAC activity by ITF2357 ameliorates joint inflammation and prevents cartilage and bone destruction in experimental arthritis. Mol Med 2011;17:391-6.
21. Nasu Y, Nishida K, Miyazawa S et al. Trichostatin A, a histone deacetylase inhibitor, suppresses synovial inflammation and subsequent cartilage destruction in a collagen antibody-induced arthritis mouse model. Osteoarthritis Cartilage 2008;16:723-32.
22. Vojinovic J, Damjanov N, D'Urzo C et al. Safety and efficacy of an oral histone deacetylase inhibitor in systemiconset juvenile idiopathic arthritis. Arthritis Rheum 2011;63: 1452-8.
23. Horiuchi M, Morinobu A, Chin T et al. Expression and function of histone deacetylases in rheumatoid arthritis synovial fibroblasts. J Rheumatol 2009;36:1580-9.
24. Kawabata T, Nishida K, Takasugi K et al. Increased activity and expression of histone deacetylase 1 in relation to tumor necrosis factor-alpha in synovial tissue of rheumatoid arthritis. Arthritis Res Ther 2010;12:R133.
25. Cantley MD, Bartold PM, Marino V et al. Histone deacetylase inhibitors and periodontal bone loss. J Periodontal Res 2011;46:697-703.
26. Kahnberg P, Lucke AJ, Glenn MP et al. Design, synthesis, potency, and cytoselectivity of anticancer agents derived by parallel synthesis from alpha-aminosuberic acid. J Med Chem 2006;49:7611-22.
27. Wheatley NC, Andrews KT, Tran TL et al. Antimalarial histone deacetylase inhibitors containing cinnamate or NSAID components. Bioorg Med Chem Lett 2010;20: 7080-4.
28. Gupta P, Reid RC, Iyer A, Sweet MJ, Fairlie DP. Towards isozyme-selective HDAC inhibitors for interrogating disease. Curr Top Med Chem 2012;12:1479-99.
29. Cantley MD, Fairlie DP, Bartold PM et al. Inhibitors of histone deacetylases in class I and class II suppress human osteoclasts in vitro. J Cell Physiol 2011;226: 3233-41.
30. Haynes DR, Wright PF, Whitehouse MW, Vernon-Roberts B. The cyclo-oxygenase inhibitor, piroxicam, enhances cytokine-induced lymphocyte proliferation in vitro and in vivo. Immunol Cell Biol 1990;68 Pt 4:225-30.
31. Alias E, Dharmapatni AS, Holding AC et al. Polyethylene particles stimulate expression of ITAM-related molecules in peri-implant tissues and when stimulating osteoclastogenesis in vitro. Acta Biomater 2012;8:3104-12.
32. Granfar RM, Day CJ, Kim MS, Morrison NA. Optimised real-time quantitative PCR assays for RANKL regulated genes. Mol Cell Probes 2005;19:119-26.
33. Franssen ME, Zeeuwen PL, Vierwinden G et al. Phenotypical and functional differences in germinative subpopulations derived from normal and psoriatic epidermis. J Invest Dermatol 2005;124:373-83.
34. T method. Nat Protoc 2008;3:1101-8.
35. Cantley MD, Haynes DR, Marino V, Bartold PM. Preexisting periodontitis exacerbates experimental arthritis in a mouse model. J Clin Periodontol 2011;38:532-41.
36. Udagawa N, Takahashi N, Akatsu T et al. The bone marrow-derived stromal cell lines MC3T3-G2/PA6 and ST2 support osteoclast-like cell differentiation in cocultures with mouse spleen cells. Endocrinology 1989;125: 1805-13.
37. Kim HN, Ha H, Lee JH et al. Trichostatin A inhibits osteoclastogenesis and bone resorption by suppressing the induction of c-Fos by RANKL. Eur J Pharmacol 2009; 623:22-9.
38. Kelly RD, Cowley SM. The physiological roles of histone deacetylase (HDAC) 1 and 2: complex co-stars with multiple leading parts. Biochem Soc Trans 2013;41: 741-9.
39. Fischle W, Dequiedt F, Fillion M et al. Human HDAC7 histone deacetylase activity is associated with HDAC3 in vivo. J Biol Chem 2001;276:35826-35.
40. Kim JH, Kim K, Youn BU et al. RANKL induces NFATc1 acetylation and stability via histone acetyltransferases during osteoclast differentiation. Biochem J 2011;18:18.
41. Takayanagi H. Mechanistic insight into osteoclast differentiation in osteoimmunology. J Mol Med 2005;83: 170-9.
42. Koch AE, Kunkel SL, Harlow LA et al. Enhanced production of monocyte chemoattractant protein-1 in rheumatoid arthritis. J Clin Invest 1992;90:772-9.
43. Kim MS, Day CJ, Selinger CI et al. MCP-1-induced human osteoclast-like cells are tartrate-resistant acid phosphatase, NFATc1, and calcitonin receptor-positive but require receptor activator of NFkB ligand for bone resorption. J Biol Chem 2006;281:1274-85.
44. Wolpe SD, Davatelis G, Sherry B et al. Macrophages secrete a novel heparin-binding protein with inflammatory and neutrophil chemokinetic properties. J Exp Med 1988; 167:570-81.
45. Ryu OH, Choi SJ, Linares AM et al. Gingival epithelial cell expression of macrophage inflammatory protein-1alpha induced by interleukin-1beta and lipopolysaccharide. J Periodontol 2007;78:1627-34.
46. Miyamoto K, Ninomiya K, Sonoda KH et al. MCP-1 expressed by osteoclasts stimulates osteoclastogenesis in an autocrine/paracrine manner. Biochem Biophys Res Commun 2009;383:373-7.
47. Culley KL, Hui W, Barter MJ et al. Class I histone deacetylase inhibition modulates metalloproteinase expression and blocks cytokine-induced cartilage degradation. Arthritis Rheum 2013;65:1822-30.
48. Hsieh IN, Liou JP, Lee HY et al. Preclinical anti-arthritic study and pharmacokinetic properties of a potent histone deacetylase inhibitor MPT0G009. Cell Death Dis 2014;5: e1166.
49. Koch AE, Kunkel SL, Harlow LA et al. Macrophage inflammatory protein-1 alpha. A novel chemotactic cytokine for macrophages in rheumatoid arthritis. J Clin Invest 1994;93:921-8.